Clinical Trials: SEARCH[STUDY] TILT[STUDY:STUDY-FIRST-POSTED] ( Novartis [STUDY:SPONSOR-COLLABORATORS] )
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 … 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 Next Last
#
NCTID/Status
Study
Last Changed
1
NCT02427750
Completed
Completed
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
Conditions: Human Influenza
Intervention: Aggripal®
Conditions: Human Influenza
Intervention: Aggripal®
September 22, 2015
2
NCT02177032
Completed
Completed
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
Conditions: Rabies Infection
Intervention: Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins, Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins
Conditions: Rabies Infection
Intervention: Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins, Rabies Vaccine, Rabies Vaccines + Rabies Immunoglobulins
February 21, 2017
3
NCT02141516
Completed
Completed
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
Conditions: Meningococcal Disease
Intervention: RMenB+OMV, RMenB+OMV, RMenB+OMV
Conditions: Meningococcal Disease
Intervention: RMenB+OMV, RMenB+OMV, RMenB+OMV
December 22, 2016
4
NCT02099149
Withdrawn
Withdrawn
Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days
Conditions: Invasive Group B Streptococcus Disease
Conditions: Invasive Group B Streptococcus Disease
July 23, 2014
5
NCT01973218
Completed
Completed
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.
Conditions: Meningococcal Disease
Intervention: Meningococcal B Recombinant Vaccine RMenB+OMV NZ, Placebo, Meningococcal ACWY-CRM Conjugate Vaccine
Conditions: Meningococcal Disease
Intervention: Meningococcal B Recombinant Vaccine RMenB+OMV NZ, Placebo, Meningococcal ACWY-CRM Conjugate Vaccine
October 5, 2015
6
NCT01867021
Completed
Completed
Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Conditions: Influenza
Intervention: Fluvirin(TIVf), Agriflu (TIV)
Conditions: Influenza
Intervention: Fluvirin(TIVf), Agriflu (TIV)
September 29, 2014
7
NCT01547715
Completed
Completed
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India
Conditions: Bacterial Meningitis
Intervention: Meningococcal ACWY Conjugate Vaccine
Conditions: Bacterial Meningitis
Intervention: Meningococcal ACWY Conjugate Vaccine
September 10, 2018
8
NCT01466387
Completed
Completed
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
Conditions: Meningococcal Disease; Meningococcal Meningitis; Typhoid; Yellow Fever; Rabies; Japanese Encephalitis
Intervention: Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine, Rabies Vaccine, MenACWY-CRM Vaccine
Conditions: Meningococcal Disease; Meningococcal Meningitis; Typhoid; Yellow Fever; Rabies; Japanese Encephalitis
Intervention: Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine, Rabies Vaccine, MenACWY-CRM Vaccine
February 7, 2014
9
NCT01446289
Completed
Completed
Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings
Conditions: Streptococcal Infection; Gram-positive Bacterial Infection; Bacterial Infection
Intervention: Group B Streptococcus Trivalent Vaccine, Placebo
Conditions: Streptococcal Infection; Gram-positive Bacterial Infection; Bacterial Infection
Intervention: Group B Streptococcus Trivalent Vaccine, Placebo
September 5, 2014
10
NCT01434680
Completed
Completed
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV
March 13, 2017
11
NCT01478347
Completed
Completed
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Recombinant Meningococcal B + OMV NZ
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Recombinant Meningococcal B + OMV NZ
March 6, 2015
12
NCT01424644
Completed
Completed
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
Conditions: Meningococcal Meningitis
Intervention: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Conditions: Meningococcal Meningitis
Intervention: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
January 21, 2014
13
NCT01423084
Completed
Completed
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Serogroup B Meningococcal Vaccine
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Serogroup B Meningococcal Vaccine
February 3, 2015
14
NCT01410474
Completed
Completed
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
Conditions: Bacterial Meningitis
Intervention: Meningococcal ACWY Conjugate Vaccine
Conditions: Bacterial Meningitis
Intervention: Meningococcal ACWY Conjugate Vaccine
September 16, 2014
15
NCT01452464
Completed
Completed
Safety of MenACWY-CRM Vaccination in Adolescents
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM
February 25, 2015
16
NCT01613677
Withdrawn
Withdrawn
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
Conditions: Treatment for Metastatic or Locally Advanced Cervical Cancer
Intervention: BKM120
Conditions: Treatment for Metastatic or Locally Advanced Cervical Cancer
Intervention: BKM120
April 19, 2017
17
NCT01586962
Completed
Completed
Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI
Conditions: Upper Respiratory Infections
Intervention: IFF Flavor 316 282, Paracetamol, Pseudoephedrine
Conditions: Upper Respiratory Infections
Intervention: IFF Flavor 316 282, Paracetamol, Pseudoephedrine
August 6, 2013
18
NCT01576809
Completed
Completed
Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)
Conditions: Upper Respiratory Infections
Intervention: IFF Flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
Conditions: Upper Respiratory Infections
Intervention: IFF Flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
October 18, 2013
19
NCT01052935
Completed
Completed
A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine
Conditions: Group B Streptococcus (GBS) Disease
Intervention: Group B Streptococcus (GBS) Vaccine
Conditions: Group B Streptococcus (GBS) Disease
Intervention: Group B Streptococcus (GBS) Vaccine
June 9, 2017
20
NCT00973349
Completed
Completed
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
Conditions: Influenza
Intervention: MF59-eH1N1_f
Conditions: Influenza
Intervention: MF59-eH1N1_f
October 29, 2015
21
NCT01018732
Completed
Completed
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Novartis Meningococcal (MenACWY-CRM) Vaccine
Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Novartis Meningococcal (MenACWY-CRM) Vaccine
July 14, 2015
22
NCT00956761
Completed
Completed
Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
Conditions: Seasonal Influenza
Intervention: Seasonal Influenza Vaccine (MF59C.1)
Conditions: Seasonal Influenza
Intervention: Seasonal Influenza Vaccine (MF59C.1)
December 21, 2015
23
NCT00956449
Completed
Completed
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects
Conditions: Influenza; Seasonal Influenza
Intervention: Seasonal Influenza Vaccine
Conditions: Influenza; Seasonal Influenza
Intervention: Seasonal Influenza Vaccine
March 24, 2017
24
NCT00996307
Completed
Completed
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
Conditions: Influenza
Intervention: MF59-eH1N1_f, MF59-eH1N1_f, MF59-eH1N1_f, MF59-eH1N1_f
Conditions: Influenza
Intervention: MF59-eH1N1_f, MF59-eH1N1_f, MF59-eH1N1_f, MF59-eH1N1_f
April 19, 2017
25
NCT00945841
Completed
Completed
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
Conditions: Seasonal Influenza
Intervention: Inactivated Split Influenza Vaccine
Conditions: Seasonal Influenza
Intervention: Inactivated Split Influenza Vaccine
April 5, 2017
26
NCT00848887
Completed
Completed
A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age
Conditions: Influenza
Intervention: Adjuvanted And Un-adjuvanted Influenza Vaccines
Conditions: Influenza
Intervention: Adjuvanted And Un-adjuvanted Influenza Vaccines
January 23, 2014
27
NCT00841763
Completed
Completed
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
Conditions: Pandemic Influenza Disease
Intervention: Placebo, Trivalent Influenza Virus Vaccine (TIV), Adjuvanted Monovalent Influenza Virus Vaccine (aH5N1), Adjuvanted Trivalent Influenza Vaccine (aTIV)
Conditions: Pandemic Influenza Disease
Intervention: Placebo, Trivalent Influenza Virus Vaccine (TIV), Adjuvanted Monovalent Influenza Virus Vaccine (aH5N1), Adjuvanted Trivalent Influenza Vaccine (aTIV)
January 18, 2013
28
NCT00806195
Completed
Completed
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis; Meningococcal Infection
Intervention: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus Influenza B) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal Conjugate Vaccine, MMR (Measles, Mumps, And Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Conditions: Meningitis; Meningococcal Infection
Intervention: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus Influenza B) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal Conjugate Vaccine, MMR (Measles, Mumps, And Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
May 13, 2013
29
NCT00694460
Completed
Completed
Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers
Conditions: Rabies; Japanese Encephalitis; Pre-Exposure Prophylaxis
Intervention: Three 1 ML Doses Of Rabies Vaccine And Two JE Vaccine, Three 0.5 ML Doses Of Rabies Vaccine And Two JE Vaccine, Three 0.1mL Doses Of Rabies Vaccine And Two JE Vaccine, Two 0.1mL Doses Of Rabies Vaccine And Two JE Vaccine, Two Doses Of JE Vaccine
Conditions: Rabies; Japanese Encephalitis; Pre-Exposure Prophylaxis
Intervention: Three 1 ML Doses Of Rabies Vaccine And Two JE Vaccine, Three 0.5 ML Doses Of Rabies Vaccine And Two JE Vaccine, Three 0.1mL Doses Of Rabies Vaccine And Two JE Vaccine, Two 0.1mL Doses Of Rabies Vaccine And Two JE Vaccine, Two Doses Of JE Vaccine
June 9, 2008
30
NCT00649883
Completed
Completed
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
Conditions: Influenza
Intervention: Influenza Trivalent Inactivated Vaccines Novartis, Influenza Trivalent Inactivated Vaccines
Conditions: Influenza
Intervention: Influenza Trivalent Inactivated Vaccines Novartis, Influenza Trivalent Inactivated Vaccines
April 5, 2017
31
NCT00645411
Completed
Completed
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Conditions: Influenza
Intervention: Cell Culture-derived Influenza Subunit Vaccine (cTIV), Egg Derived Influenza Subunit Vaccine (eTIV), Cell Culture-derived Influenza Subunit Vaccine (cTIV), Egg Derived Influenza Subunit Vaccine (eTIV)
Conditions: Influenza
Intervention: Cell Culture-derived Influenza Subunit Vaccine (cTIV), Egg Derived Influenza Subunit Vaccine (eTIV), Cell Culture-derived Influenza Subunit Vaccine (cTIV), Egg Derived Influenza Subunit Vaccine (eTIV)
October 20, 2015
32
NCT00644059
Completed
Completed
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
Conditions: Influenza, Human
Intervention: Adjuvanted Trivalent Inactivated Subunit Influenza Vaccine, Non-adjuvanted Trivalent Inactivated Subunit Influenza Vaccine Or Non-adjuvanted Trivalent Inactivated Split Influenza Vaccine, Meningococcal C Conjugate Vaccine Or Tick-borne Encephalitis Vaccine
Conditions: Influenza, Human
Intervention: Adjuvanted Trivalent Inactivated Subunit Influenza Vaccine, Non-adjuvanted Trivalent Inactivated Subunit Influenza Vaccine Or Non-adjuvanted Trivalent Inactivated Split Influenza Vaccine, Meningococcal C Conjugate Vaccine Or Tick-borne Encephalitis Vaccine
August 31, 2015
33
NCT00579345
Completed
Completed
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
Conditions: Influenza
Intervention: Cell Culture Derived Seasonal Trivalent Influenza Vaccine (cTIV), Influenza Virus Vaccine (egg-derived Seasonal Trivalent, Thiomersal Free; ETIV_a)., CTIV Or ETIV_a, CTIV+PV OR ETIV_a+PV
Conditions: Influenza
Intervention: Cell Culture Derived Seasonal Trivalent Influenza Vaccine (cTIV), Influenza Virus Vaccine (egg-derived Seasonal Trivalent, Thiomersal Free; ETIV_a)., CTIV Or ETIV_a, CTIV+PV OR ETIV_a+PV
November 30, 2016
34
NCT00559975
Completed
Completed
Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine
Conditions: Influenza Infection
Intervention: Subunit Influenza Vaccine, Adjuvanted Influenza Vaccine, Adjuvanted Influenza Vaccine Combined With CpG7909, Adjuvanted Influenza Vaccine Combine With CpG7909, Adjuvanted Influenza Vaccine Combine With CpG7909
Conditions: Influenza Infection
Intervention: Subunit Influenza Vaccine, Adjuvanted Influenza Vaccine, Adjuvanted Influenza Vaccine Combined With CpG7909, Adjuvanted Influenza Vaccine Combine With CpG7909, Adjuvanted Influenza Vaccine Combine With CpG7909
November 4, 2009
35
NCT00601731
Completed
Completed
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM197, Blood Test
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM197, Blood Test
October 14, 2014
36
NCT00498303
Completed
Completed
Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008
Conditions: Seasonal Influenza; Vaccine
Intervention: Trivalent Split Influenza Vaccine
Conditions: Seasonal Influenza; Vaccine
Intervention: Trivalent Split Influenza Vaccine
April 21, 2008
37
NCT00481065
Completed
Completed
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
Conditions: Pandemic; Avian Influenza
Intervention: MF59-eH5N1, ETIV_a, MF59-eH5N1 + ETIV_a
Conditions: Pandemic; Avian Influenza
Intervention: MF59-eH5N1, ETIV_a, MF59-eH5N1 + ETIV_a
December 31, 2013
38
NCT00464672
Completed
Completed
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
Conditions: Influenza
Intervention: Influenza Virus Vaccine, Comparator Influenza Vaccine
Conditions: Influenza
Intervention: Influenza Virus Vaccine, Comparator Influenza Vaccine
September 16, 2015
39
NCT00488683
Completed
Completed
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM, DTaP-Hib-IPV, PCV, MMR, Hib
Conditions: Meningococcal Disease
Intervention: MenACWY-CRM, DTaP-Hib-IPV, PCV, MMR, Hib
September 18, 2014
40
NCT00452621
Completed
Completed
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
Conditions: Encephalitis, Tick-Borne
Intervention: Blood Draw
Conditions: Encephalitis, Tick-Borne
Intervention: Blood Draw
April 22, 2008
41
NCT00434733
Completed
Completed
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
Conditions: Influenza
Intervention: Pandemic Influenza Vaccine
Conditions: Influenza
Intervention: Pandemic Influenza Vaccine
April 23, 2008
42
NCT00354016
Completed
Completed
Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly Subjects
Conditions: Influenza
Intervention: Preservative Free Inactivated Split Influenza Vaccine Using The Strain Composition 2006/2007
Conditions: Influenza
Intervention: Preservative Free Inactivated Split Influenza Vaccine Using The Strain Composition 2006/2007
March 12, 2007
43
NCT00342940
Withdrawn
Withdrawn
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
Conditions: Influenza
Intervention: Influenza Surface Antigen Inactivated Vaccine
Conditions: Influenza
Intervention: Influenza Surface Antigen Inactivated Vaccine
April 19, 2017
44
NCT00329966
Completed
Completed
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
Conditions: Influenza
Intervention: Surface Antigen, Inactivated, Influenza (form.2006-07)
Conditions: Influenza
Intervention: Surface Antigen, Inactivated, Influenza (form.2006-07)
September 13, 2006
45
NCT00329927
Completed
Completed
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects
Conditions: Influenza
Intervention: Surface Antigen, Inactivated, (Adjuvanted With MF59C.1), Form. 2006-07
Conditions: Influenza
Intervention: Surface Antigen, Inactivated, (Adjuvanted With MF59C.1), Form. 2006-07
September 13, 2006
46
NCT00316628
Completed
Completed
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.
Conditions: Influenza
Intervention: Influenza Vaccine
Conditions: Influenza
Intervention: Influenza Vaccine
September 13, 2006
47
NCT00316615
Completed
Completed
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
Conditions: Influenza Disease
Intervention: Influenza Vaccine
Conditions: Influenza Disease
Intervention: Influenza Vaccine
September 13, 2006
48
NCT00311493
Completed
Completed
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
Conditions: Encephalitis, Tick-Borne
Intervention: Tick-Borne Encephalitis Vaccine
Conditions: Encephalitis, Tick-Borne
Intervention: Tick-Borne Encephalitis Vaccine
March 12, 2007
49
NCT00311480
Completed
Completed
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
Conditions: Pandemic Influenza Disease
Intervention: Influenza Vaccine Surface Antigen Adjuvanted With MF59
Conditions: Pandemic Influenza Disease
Intervention: Influenza Vaccine Surface Antigen Adjuvanted With MF59
March 12, 2007
50
NCT00311441
Completed
Completed
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
Conditions: Encephalitis, Tick-Borne
Intervention: Tick-Borne Encephalitis Vaccine
Conditions: Encephalitis, Tick-Borne
Intervention: Tick-Borne Encephalitis Vaccine
March 14, 2008
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 … 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 Next Last
Last Updated
The last updated date is the most recent date when changes to a clinical trial were
submitted to ClinicalTrials.gov. There is often a delay of a few days before the
updated trial is available on the clinical trials website.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Specify a From date to find the most recently changed trials. Specify both From and To dates to find trials changed during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
First Received
The first received date is the date when the clinical trial was first submitted
to ClinicalTrials.gov. There is often a delay of a few days before the
trial is available on the clinical trials website.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Clinical trial records are often updated after they have been published. The first received, last updated, start, and end dates are all displayed in the full text view of the clinical trial.
Specify a From date to find the most recent trials. Specify both From and To dates to find trials submitted during a certain period. If no dates are given, all trials will be included.
Dates should be given in a MM/DD/YYYY format, as in 1/1/2006 or 8/17/2004.
Safety Issue
If selected, restricts search results to those studies which have
an outcome measure designated as a safety issue. Note that this is a
poor estimate of the safety of a treatment or intervention, but it is
all we have now.
Funded By
Studies are supported by one or more organizations called sponsors.
Support includes contributions of facilities, expertise, and/or financial resources.
All sponsors in the database have been assigned one of the following organization types:
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
National Institutes of Health (NIH)
Other U.S. Federal Agency - Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs (VA), etc.
Industry - the pharmaceutical companies
University/Organization - all others, including community-based organizations
Click the check box to the left of each organization type that you wish to include in your search. You can select more than one organization type. If you do not select any type, all types will be included.
Study Phase
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions
that study is seeking to answer:
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.
In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.
These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.
Click the check box to the left of each study phase that you wish to include in your search. You can select more than one study phase. If you do not select a any phase, all phases will be included.
Age Group
Studies may be designed for participants of particular ages:
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Children (birth-17 yrs old)
Adults (18-65 yrs old)
Senior (66+ yrs old)
Click the check box to the left of each age group that you wish to include in your search. You can select more than one age group. If you do not select a any group, all groups will be included.
Gender
Searches can be restricted to studies which accept female or male participants.
Location Terms
If you are interested in a specific city (such as Los Angeles) or facility
name (such as the Mayo Clinic), enter it as a location term. Not all studies
include this level of detail, but if they do, this will find them.
Countries and States
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state.
Study IDs
Each trial is assigned one or more identification numbers by the institute, agency,
or organization sponsoring the trial. In addition, clinical trials assigns a
unique NCT identifier of the form NCTxxxxxxxx where each x is a numeric digit.
Use this box to search for a trial by NCT identifier or any other study
identification numbers.
Examples:
Examples:
NCT00001789
97-h-0197
ia0006
actg 076
97-h-0197
ia0006
actg 076
Sponsor (Lead)
Use this box to specify the name of an institute, organization, or company that is
conducting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
A search in this area will check only the sponsor field. To also look for collaborators, use the Sponsor/Collaborators search box.
When the Exact Match checkbox is checked, the sponsor name in the study must exactly match the sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Sponsor/Collaborators
Use this box to specify institutes, organizations, or companies that are
conducting or otherwise supporting a trial.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the sponsor is decided by the data provider.
Searching this area will look in both the sponsor field and in the collaborators field. To only look in the sponsor field, use the Sponsor (Lead) search box.
When the Exact Match checkbox is checked, the name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Examples:
National Cancer Institute
Mayo Clinic
Bristol-Myers Squibb
Outcome Measures
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Outcome measures are used to evaluate trial results. For example, an obesity treatment
might be evaluated by a measure of weight loss after 6 months. Measures can also be used
to quantify side effects, such as number of myocardial infarctions,
number of patients with heart arrhythmia, number of suicides, etc.
Use this box to specify an outcome measure used to evaluate trial results.
Examples:
weight loss
heart failure
suicide
Interventions
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied.
Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Use this box to specify drugs, devices, procedures, or vaccines used in a trial.
Examples:
clofibrate
cyclosporine
vitamin e
Conditions
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In ClinicalTrials.gov,
conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.
Use this box to specify the conditions being studied.
Examples:
lupus
heart attack
leukemia
risk factors for breast cancer
Study Type
There are three types of studies available in ClinicalTrials.gov:
There are three types of studies available in ClinicalTrials.gov:
Interventional:
Observational:
Expanded Access:
Studies where individuals are assigned to receive specific interventions.
Participants may receive diagnostic, therapeutic or other types of interventions.
Assignment of the intervention may or may not be random.
Individuals are tracked and biomedical and/or health outcomes are assessed.
Observational:
Studies without an intervention.
Studies where biomedical and/or health outcomes are assessed in a pre-defined group of individuals.
Participants may receive diagnostic, therapeutic, or other interventions, but the investigator
does not assign specific interventions to the participants of the study.
Expanded Access:
Records describing the procedure for obtaining an experimental drug or device for patients who
are failing on currently available treatments for their condition and also are unable to
participate in ongoing clinical trials. Expanded Access records are used to register all
types of non-protocol access to experimental treatments, including protocol exception,
single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.
Study Results
Searches can be restricted to studies with or without results.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
The inclusion of study results is a relatively new feature of ClinicalTrials.gov. Collection of results began in September of 2008. Almost all older studies and some newer studies do not include results. As time goes on, there will be more results available.
Recruitment Status
Also known as Enrollment Status.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Not all clinical trials in this database are accepting new participants. If you are looking for studies that are currently recruiting participants, will be recruiting in the future, or are about drugs that are available for expanded access, select Open Studies in the recruitment menu.
If you are interested in all trials, whether they are recruiting new participants or not, leave the menu with All Studies selected.
Trials may not be recruiting because they are full, completed, or halted for various reasons. In addition, some trials have very restrictive eligibility requirements and must seek participants by invitation only. To see these studies, Select Closed Studies in the recruitment menu.
Full list of all possible recruitment status values:
Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Search Terms
Use this box to specify general search terms found anywhere in the trial record.
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Multiple terms can be separated by an AND (all uppercase).
Examples:
type ii diabetes
veterans affairs medical center
heart attacks in older adults
nhlbi AND heart disease
Cisplatin AND safety study
Help for Searching clinical trials
Help Topics:
Basic Search:
On the Basic Search page, enter a word or word(s) that you want to use to find studies.
These may include diseases, interventions, and/or locations.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Medical terms are often several words long, such as Percutaneous Coronary Intervention. To only find studies where the words are together as a phrase, put the term in quotes (e.g., "Percutaneous Coronary Intervention"). If you search for a multi-word term without quotes, studies with all words together as a phrase will appear higher in the results list than studies where the words are separated and spread throughout the document. For example, a search for Heart Attack will list a study about,
Use of a Pacemaker Following a Heart Attack.
higher than the study,
Heart Defects and Transient Ischemic Attacks
A search for "Heart Attack" would not find the second study. Synonyms are known for some terms and are used where possible. For example, a search for Heart Attack will also find occurrences of Myocardial Infarction.
Advanced Search:
Many searches are a single term and can be performed with a few words in the
search box. But, sometimes you need more control. Click on the Advanced Search tab
(if starting a new search) or Refine Search tab (if modifying an existing search)
to show additional search fields.
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Recruitment:
Interventions:
Outcomes Measures:
Sponsor/Collaborators:
Sponsor (Lead):
Study IDs:
Country/State:
Location Terms:
Gender:
Age Group:
Phase:
Funded By:
Safety Issue:
First Received:
Last Updated:
The additional search fields can be used to limit your search results. Note that it is not necessary to fill in all the fields, only those that are needed for your search. If you are finding too few studies, consider clearing a field and searching again.
Search Terms:
Performs a general search in all sections of the study record, including title,
description, conditions, interventions, locations, etc. Terms in this field are
searched the same as Basic Search.
Recruitment:
Limits search results to studies that are open or closed. New volunteers may be
able to participate in open studies, but not closed studies.
Open recruitment status values:
Closed recruitment status values:
Values are color coded (as shown) in the search results.
Study Results:Open recruitment status values:
Recruiting,
Not yet recruiting, or
Available for expanded access.
Not yet recruiting, or
Available for expanded access.
Closed recruitment status values:
Active, not recruiting,
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Completed,
Terminated,
Suspended,
Withdrawn,
Enrolling by invitation,
Temporarily not available for expanded access,
No longer available for expanded access,
Approved for marketing, or
Unknown.
Values are color coded (as shown) in the search results.
Limits search results based on whether the study has results or not:
Study Type:
All Studies,
Studies With Results, or
Studies Without Results
The inclusion of Study Results is a new feature of ClinicalTrials.gov.
Only a few studies have results available.Studies With Results, or
Studies Without Results
Limits search results to any of the following study types:
Conditions:
Interventional,
Observational, or
Expanded Access
Observational, or
Expanded Access
Performs a search on fields describing the diseases or conditions being studied.
Interventions:
Performs a search on fields listing the drugs or interventions being studied.
Outcomes Measures:
Performs a search on fields listing the outcome measures used to quantify study results.
Sponsor/Collaborators:
Performs a search on fields listing the sponsor and collaborators of a study.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
When the Exact Match checkbox is checked, the sponsor/collaborator name in the study must exactly match the name in the search. For example, if unchecked, a search for Merck in the sponsor/collaborator field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Sponsor (Lead):
Performs a search on the sponsor field of a study.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
It is common for several organizations to collaborate by providing funding, facilities, experimental treatments, etc. Which organization is considered the "sponsor" is decided by the data provider.
When the Exact Match checkbox is checked, the lead sponsor name in the study must exactly match the lead sponsor name in the search. For example, if unchecked, a search for Merck in the lead sponsor field will find Merck, Merck KGaA, Dupont Merck, and Merck Sharp & Dohme. When checked, only Merck, with no other words in the name, will be found.
Study IDs:
Performs a search on fields listing ID numbers.
Country/State:
Trials are often conducted at many locations around the world.
Select up to three locations to find trials conducted in
specific countries. Some countries (currently limited to the
United States, Canada, and Australia), locations can be narrowed
further by selecting a state (e.g., United States, Alabama).
Location Terms:
Finds studies in specific locations such as a city (Los Angeles) or facility (Mayo Clinic).
Not all studies include this level of detail, but if they do, this will find them.
Gender:
Limits search results to those studies that accept female or male participants.
Age Group:
Limits search results to those studies that include at least one of the specified age
ranges. More than one age group can be selected.
Phase:
Limits search results to studies that are labeled with at least one of the specified
phases. More than one Phase can be selected.
Funded By:
Limits search results to studies that have at least one sponsor of the specified types.
More than one sponsor type can be selected.
Safety Issue:
Limits search results to studies that have at least one outcome measure designated as a safety issue.
First Received:
Limits search results to studies that were received by clinical trials within a
specified date range. The "From" or "To" field can be left blank.
Last Updated:
Limits search results to studies that were modified within a
specified date range. The "From" or "To" field can be left blank.
Refine Search:
Searches display a list of studies found (List Results tab). If you are not content with
the search results, click on the Refine Search tab at the top of the list to modify your
search.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
When you are done making changes, click Search to display the new results.
Add terms to empty fields to search within your current result. You can also add terms to fields that contain terms. For best results, use an AND (all upper case) as a separator between terms in the same field.
For example:
heart attack
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
heart attack AND aspirin
heart attack AND aspirin AND older adults
heart attack AND aspirin AND older adults AND California
When you are done making changes, click Search to display the new results.
Search Expressions:
Use AND (all upper case) to find study records that contain all terms connected by AND.
For example:
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.
For example:
prostate cancer AND radiation
heart disease AND stroke AND California
heart disease AND stroke AND California
Use OR (all upper case) to find study records that contain either term connected by OR.
For example:
Aspirin OR ibuprofen
heart disease OR heart attack
heart disease OR heart attack
Use NOT (all upper case) to find study records that do not contain the term following NOT.
For example:
Immunodeficiency NOT AIDS
Likewise, AND, OR, NOT, and parentheses can be used to create more complicated search expressions.
For example:
prostate cancer AND NOT ( radiation OR homeopathic remedies )
( heart disease OR heart attack ) AND ( stroke OR clot )
( heart disease OR heart attack ) AND ( stroke OR clot )
Note that the use of AND and OR as logical operators can be confusing.
An appropriate search for a list such as,
Ear, Nose, and Throat Conditions
is the expression
( Ear OR Nose OR Throat ) AND Conditions
Fortunately, search will do a pretty good job of finding the right studies either way.To search for AND as a word, instead of using it as an operator, put it in quotes.
Likewise, you can quote OR, NOT, and parentheses.